Which elements have the biggest impact on study costs? Which areas are most often underestimated?
Every clinical, medical or observational study is unique — complex, resource-intensive and requiring strong operational coordination. Proper budget estimation affects both project success and financial stability. With over 20 years of experience, the BioStat team helps sponsors avoid common financial mistakes that can escalate into significant avoidable costs.
The largest portion of the budget typically relates to clinical site activities — investigator and staff fees, diagnostic procedures, consumables and recruitment costs. This is also the area most prone to underestimation, especially when sponsors overlook site-to-site variability or overestimate recruitment speed. BioStat supports sponsors in defining realistic per-patient fees and anticipating variable factors such as seasonality or regulatory approval timelines.
Monitoring is another major cost component. Ensuring GCP compliance requires regular CRA visits, source data verification and reporting. Underestimating the number of visits or CRA workload is a common issue that leads to data quality problems. BioStat applies proven, study-specific monitoring cost models aligned with study design and phase.
Sponsors frequently underestimate data management and biostatistics costs, including eCRF design, validation, data cleaning, query management and final analysis.
Budgeting for pharmacovigilance is also often overlooked. Safety oversight — SAE reporting, SUSAR notifications, communication with regulators, translations and ongoing safety analysis — requires 24/7 availability and specialised expertise. BioStat provides comprehensive PV services for both commercial and publicly funded projects.
From our experience, other challenging cost components include:
• production and logistics of investigational products/placebo/comparators,
• IT infrastructure (eCRF, eTMF, hosting, backups) and system updates after protocol amendments,
• administrative and contracting activities,
• archiving, audits and translations,
• lack of contingency (buffer) for operational deviations.
Identifying these components early enables the creation of a complete, realistic and financially safe budget. BioStat supports sponsors in building transparent, precise budgets based on real-world data from hundreds of completed projects.
If you want to ensure your investment in clinical research is well-planned and cost-effective, we offer complimentary expert consultations.
